In addition, the combination of monitoring HSF1 expression by immunostaining along with HSF1 small molecular inhibitors may be a useful strategy to target AML residual disease just as done for PD-L1 expression with Keytruda and HER2 expression with Trastuzumab in the recently described companion diagnostics79. The gene discussed is CD274; the disease is acute myeloid leukemia.